Black Diamond Therapeutics, Inc.

NasdaqGS BDTX

Black Diamond Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -81.02 M

Black Diamond Therapeutics, Inc. EBITDA is USD -81.02 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 6.98% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Black Diamond Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -87.09 M, a 9.59% change year over year.
Black Diamond Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -96.34 M, a 21.73% change year over year.
Black Diamond Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -123.08 M, a -123.79% change year over year.
Black Diamond Therapeutics, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -55.00 M, a -93.50% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: BDTX

Black Diamond Therapeutics, Inc.

CEO	Dr. Mark A. Velleca M.D., Ph.D.
IPO Date	Jan. 31, 2020
Location	United States
Headquarters	One Main Street
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years